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The aims of this study are to investigate the occurrence characteristics of Acanthopanax (刺五加 cì wǔ jia)
anaphylactic shock and to provide objective evidence for the rational use of the medicine. Fifty-seven
cases of Acanthopanax anaphylactic shock were collected from several professional databases in China.
The statistical data of the patients were analyzed with Visual FoxPro 6.0 and Ofﬁce Excel 2003 by
Microsoft (Redmond, WA, USA). The male:female incidence ratio was 0.5:1. Fifty-six (98.25%) patients
were older than 30 years. Thirty-nine (68.42%) patients had an unknown allergy history. Nine (15.79%)
patients used Acanthopanax for unlabeled indications. In most (98.25 %) patients, Acanthopanaxwas used
in the form of dosage injection. Anaphylactic shock occurred within 30 minutes after treatment in 52
(94.54%) patients, and all episodes occurred during the infusion process. In two (3.51%) patients, the
episode occurred when they used Acanthopanax for the second time. In one (1.75%) patient, the episode
occurred during the third time of use. The clinical symptoms of anaphylactic shock are diversiﬁed, but all
patients presented with cardiovascular and respiratory system symptoms. Acanthopanax injections that
led to anaphylactic shock were produced exclusively by four manufacturers. Four (7.02%) patients died
and 49 (85.96%) patients were cured, but the status of four patients is unknown. Because an Acantho-
panax injection may cause anaphylactic shock and can be fatal in severe cases, physicians and patients
must pay close attention to using it rationally. Clinicians should carefully consult the allergic constitution
of their patients, strictly follow the guidelines of the drug, use Acanthopanax in the oral dosage form as
much as possible, and strengthen therapeutic monitoring.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Acanthopanax (刺五加 cì wǔ jia) injection is formulated with
extracts from the stems and leaves of Acanthopanax senticosus. It
contains a variety of active ingredients such as eleutheroside, iso-
fraxidin, and hyperoside.1 An Acanthopanax injection can dilate
blood vessels, increase coronary and cerebral blood ﬂow, reduce
myocardial oxygen consumption, improve microcirculation,2
reduce blood viscosity, scavenge free radicals,3 regulate immune
function,4 regulate bidirectionally in the central nervous system,
and reduce damage caused by virulence factors.5 In China, an
Acanthopanax injection can be applied to treat transient ischemicital, Number 10 JianNanWest
.
for Food and Biomolecules,
molecules, National Taiwan Univeattack, intracranial arteriosclerosis, intracranial thrombosis, intra-
cranial embolism, coronary disease, angina pectoris, neurasthenia,
and menopausal syndrome. An Acanthopanax injection is a neces-
sary traditional Chinese medicine (中醫 zhong yı; TCM) that is
stocked in traditional Chinese hospital emergency departments in
China. Despite widespread use, Acanthopanax could possibly lead to
anaphylactic shock. Therefore, we collected several published
Chinese literature reports on Acanthopanax anaphylactic shock to
determine its occurrence characteristics and provide an objective
basis for its clinical rational use (Fig. 1).2. Materials and methods
2.1. Materials
In three Chinese professional databases, which were variable
information processing (VIP) information, Chinese Journal Full-text
Database, and Wanfang Data, we entered keywords such asrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Technical route of this article.
Table 1
The age distribution of the cases of Acanthopanax anaphylactic shock.
Age (y) No. of
cases
Constituent
ratio (%)
Chinese
population
sample data
Chinese population
constituent ratio (%)
< 30 1 1.79 535,548 42.48
30e39 12 21.43 246,749 19.58
40e49 16 28.57 185,781 14.74
50e59 14 25.00 139,151 11.04
 60 13 23.21 153,269 12.16
Total 56 100.00 1,260,498 100.00
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Chinese literature concerning Acanthopanax anaphylactic shock.
Except for one duplicate report, 52 evaluable articles were collected
that contained 57 cases of Acanthopanax anaphylactic shock.
Relevant information data of the 57 cases were collected as
follows: (1) demographics (e.g., age, gender, allergy history); (2)
drug use (e.g., dosage form, dosage, usage, solvent, concomitant
medications, manufacturer, and production batch number); (3)
occurrence of anaphylactic shock (e.g., time of shock occurrence,
symptom distribution, complications, time to improvement or re-
covery, shock outcome); and (4) other data (e.g., reporting time of
the case).
2.2. Statistical analysis
Visual FoxPro 6.0 (Microsoft) was used to establish an “Acan-
thopanax anaphylactic shock database management system”
wherein relative data were input. A statistical analysis was then
performed on the data involving the aforementioned information
by Ofﬁce Excel 2003 (Microsoft).
3. Results
3.1. General situation of the patients
3.1.1. Gender and age distribution of the patients
There were 38 (66.67%) female patients and 19 (33.33%) male
patients. The male:female ratio was 0.5:1. This ﬁnding is consistent
with the literature reports.6 The minimum age of the patients was
18 years and themaximum agewas 97 years. Except for one patient
of unknown age, 56 (98.25%) patients were older than 30 years.
Table 1 lists the age distribution. Among these patients, the ratio of
the below-30-year-old patients to over-30-year-old patients was
1:55. However, because the sex ratio and age distribution of the
patients treated by Acanthopanax (刺五加 cì wǔ jia) is difﬁcult to
estimate accurately, further study is needed.3.1.2. Allergy history
Among the 57 patients, 39 (68.42%) patients had an unknown
allergy history, seven (12.28%) patients had a history of allergy to
drugs or food, and 11 (19.30%) patients had no allergy history.
3.2. The primary disease distribution among the patients
Among the 57 patients, the primary diseases of ﬁve (8.77%)
patients were unknown. The top three diseases were cardiovascu-
lar disease (e.g., coronary disease, angina pectoris) in 18 (31.58%)
patients, cerebrovascular disease (e.g., cerebral infarction, intra-
cranial arteriosclerosis) in ten (17.54%) patients, and neurasthenia
in eight (14.03%) patients. There were nine (15.79%) patients who
used Acanthopanax for unlabeled indications; their primary dis-
eases were renal insufﬁciency, carbon monoxide poisoning, acute
tonsillitis, fractures, hepatitis B, hyperthyroidism, cervical spon-
dylosis, and chronic bronchitis (1 patient each).
3.3. Conditions of Acanthopanax use
3.3.1. Distribution of the dosage forms
Among the 57 patients, 56 (98.25%) patients used the injection
formulation. The only exception was that one (1.75%) patient had
Table 3
System distribution of the clinical symptoms of Acanthopanax anaphylactic shock.
System
involved
Symptoms No. of
cases
Constituent
ratio (%)
Cardiovascular
system
Hypotension, chest distress, cyanosis,
coldness, palpitations or tachycardia,
fast pulse, paleness, ﬂushing, lip or
eyelid edema, weak heart sounds,
blood pressure drop to 0 mmHg, no
pulse, cardiac arrest, bradycardia
57 100
Respiratory
system
Dyspnea, fast respiration rate,
pulmonary rales or wheeze,
laryngeal or bronchial edema, three
depressions sign, respiratory arrest
57 100
Nervous
system
Sweating, dysphoria, lip or limb
numbness, shivering, fever, head
distention or dizziness, tetany,
sense of endangerment,
unconsciousness, opisthotonos,
body acupuncture-like pain, local
39 68.42
Q. Zhan / Journal of Traditional and Complementary Medicine 5 (2015) 253e257 255used > 50 tablets of Acanthopanax for suicide, which led to shock
and arrhythmias.
3.3.2. Administration and dosage
There were 51 cases of documented Acanthopanax dosage and
solvent capacity. After conversion, Table 2 lists the drug concen-
tration distribution.
3.3.3. Solvent
Among 46 patients with clear solvent records, 5% glucose in-
jection was used in 29 (63.04%) patients; 10% glucose injection, in
14 (30.43%) patients; saline injection, in two (4.35%) patients; and
glucose and sodium chloride injection, in one (2.17%) patient. Only
eight patients used a big dosage transfusion of Acanthopanax.
3.3.4. The use times of the drug
Fifty-four (94.74%) patients had used Acanthopanax for the ﬁrst
time; two (3.51%) patients, for the second time; and one (1.75%)
patient, for the third time.
3.3.5. Combined medication
Forty-two (73.68%) patients had no combined medication use;
14 (24.56%) patients used various combined medications, which
primarily included antibiotics, energy mixtures, and cardiovascular
system drugs. The combined medication use in one patient was
unknown.
3.3.6. The Acanthopanax manufacturers and batch number
The manufacturer and batch numbers were reported for 23
patients. Among these manufacturers, Heilongjiang Wandashan
Pharmaceutical Factory (Jixi city, Heilongjiang Province) produced
the injections used by 16 (69.56%) patients; Heilongjiang Wusuli
River Pharmaceutical Company Limited (Harbin city, Heilongjiang
Province) produced the injections used by four (17.39%) patients;
Heilongjiang Zhenbao Island Pharmaceutical Company Limited (Jixi
city, Heilongjiang Province) produced the injections used by two
(8.70%) patients; and Heilongjiang Duoduo Pharmaceutical Com-
pany Limited (Jia Musi city, Heilongjiang Province) produced the
injections used by one (4.35%) patient. Wandashan had three batch
numbers repeatedly reported, and Zhenbao had one batch number.
3.4. Occurrence of anaphylactic shock
3.4.1. Anaphylactic shock occurrence time distribution
Anaphylactic shock occurred in 28 (50.91%) patients within 10
minutes after treatment, in 52 (94.54%) patients within 30 minutes,
and in three (5.45%) patients after 30minutes but within 1 hour. All
shock in the patients occurred during the infusion process. In two
patients, the occurrence time of anaphylactic shock was unknown.
3.4.2. Distribution of the clinical symptoms of anaphylactic shock
The clinical symptoms of anaphylactic shock were diversiﬁed.
The top 10 common shock symptoms were as follows: hypotension
in 57 (100%) patients, dyspnea in 44 (77.19%) patients, chest distress
in 33 (57.89%) patients, cyanosis in 33 (57.89%) patients, peripheral
coldness in 30 (52.63%) patients, palpitations or tachycardia in 24Table 2
The drug concentration distribution of Acanthopanax.
Concentration (mg/mL) No. of cases Constituent ratio (%)
C ＜ 1 mg/mL 36 70.59
1 mg/mL  C＜ 2 mg/mL 7 13.72
2 mg/mL  C 8 15.69
Total 51 100.00
C ¼ concentration.(42.10%) patients, pruritus and/or exanthema in 21 (36.84%) pa-
tients, fast pulse in 21 (36.84%) patients, paleness in 20 patients
(35.09%), and sweating in 16 patients (28.07%). Twenty patients had
severe shock symptoms such as blood pressure dropping to
0 mmHg in 18 (31.58%) patients, unconsciousness in 17 (29.82%)
patients, respiratory arrest in 10 (17.54%) patients, lack of pulse in
six (10.53%) patients, urinary incontinence in four (7.02%) patients,
and cardiac arrest in three (5.26%) patients. Table 3 lists all clinical
symptoms that involve multiple systems.
3.4.3. Complications
Complications only occurred in three patients. One patient
suffering from brain edemawas transferred to another hospital and
the disease outcome is unknown. One patient suffering from
multiple organ failure died. One patient suffering from blindness
recovered 15 days after treatment.
3.4.4. Outcomes of Acanthopanax anaphylactic shock
Four patients were transferred to another hospital and their
disease outcomes are unknown. Of the remaining patients, four
(7.02%) patients died and 49 (85.96%) patients were cured. Forty-
ﬁve patients had been marked the relief time; among these, 37
(82.22%) patients experienced relief in 30 minutes, six (13.33%)
patients experienced relief in 31minutes to 1 hour, and two (4.44%)
patients experienced relief after 1 hour but within 2 hours. Thirty-
three patients had been indicated the recovery time by medical
staffs: 29 (87.88%) patients completely healed within 1 day, three
(9.09%) patients healed within 1e5 days, and one (3.03%) patient
healed in 15 days.
3.4.5. Relevance evaluation of Acanthopanax anaphylactic shock
The evaluation standard7 recommended by the Adverse Drug
Reaction Monitoring Center of the People's Republic of China is
widely used in the Chinese adverse drug reaction (ADR) reporting
system. The standard includes ﬁve points: (1) whether there is a
reasonable time sequence between the medication and the ADR;
(2) whether the ADR is consistent with the known adverse reactionskin numbness
Skin and
appendages
Pruritus and/or exanthema 18 31.58
Gastrointestinal
tract
Nausea and vomiting, abdominal
pain, diarrhea
12 21.05
Eye Visual disorder or amaurosis,
conjunctival congestion,
chemosis, papilledema
11 19.30
Urogenital
system
Urinary incontinence 4 7.02
Table 5
Time distributions of the case reports.
Year No. of cases Proportion (%)
2008e2013 6 10.53
2003e2007 26 45.61
1998e2002 23 40.35
Prior to 1997 2 3.51
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lead to the disappearance or mitigation of ADR; (4) whether the
same reaction appears again after re-exposure to the drug; and (5)
whether the ADR could be explained by the combination of other
medications or by disease progression. The relevance evaluation
result can then be concluded in accordance with Table 4. Based on
the aforementioned standard, the reactions in four (7.02%) patients
were “positive”; in 50 (87.72%) patients, “probable”; in one (1.75%)
patient, “possible”; and in two (3.51%) patients, “ doubtful”
3.4.6. Other data
Table 5 shows the time distributions of the case reports.
4. Discussion
4.1. The basic characteristics of the patients
Compared to the natural population structure, the female cases
of Acanthopanax (刺五加 cì wǔ jia) anaphylactic shock were statis-
tically and signiﬁcantly greater. Its pathogenesis is unclear and
demands further research. There also exists a signiﬁcant difference
in the distribution of age. Except for one patient, most patients
were older than 30 years. The primary reason for this deference is
that Acanthopanax is indicated for cardiovascular and cerebrovas-
cular diseases such as coronary disease and cerebral arterioscle-
rosis. Because patients older than 30 years are in a very high risk
group for these diseases, the use of Acanthopanax is greatly
increased in these patients and therefore the risk of adverse re-
actions is increased.
If the patient tends to have an allergic constitution, the risk of
drug-induced allergic reactions will be greatly increased. However,
in this paper, the allergy history of more than one-half of the re-
ported cases was unknown. This showed that the medical staff had
ignored performing consulting work on the allergic constitution of
patients. We suggest that a medical staff should carefully consult
the allergic constitution of patients to effectively observe the pa-
tient reaction in the course of treatment, and give active treatment
to the patient, as necessary.
According to our data, some patients used Acanthopanax for
unlabeled indications. This implies that the medication usage
guidelines should be strictly followed to reduce the risks of drug
treatment.
4.2. Acanthopanax use
The exact mechanism of Acanthopanax anaphylactic shock is
unclear. It may be related to the complex chemical composition of
Acanthopanax, which contains a variety of ingredients that may
cause an allergy. There are many kinds of Acanthopanax dosage
forms such as capsules, tablets, mixture, granules, and injection.
From the collected data, the Acanthopanax dosage form that results
in shock is primarily injection. This is consistent with the ﬁndingsTable 4
The standard of relevance evaluation between the drug and the adverse drug
reaction.
1 2 3 4 5
Positive þ þ þ þ e
Probable þ þ þ ? e
Possible þ þ ± ? ±
Doubtful þ e ± ? ±
Impossible e e e e þ
“þ” ¼ afﬁrmative; “” ¼ negative; “±” ¼ difﬁcult to determine as afﬁrmative or
negative; “?” ¼ situation is unclear.of a published report8 that indicates that TCM injections are more
likely to cause anaphylactic shock.
The reason TCM injections are more likely to cause anaphylactic
shock probably lies in the following four points: (1) TCM injections
contain impurities (e.g., proteins, starch, tannins, pigments, mucus,
resins, and volatile oil) that result from poor puriﬁcation tech-
niques; these impurities may act as haptens and bind to plasma
proteins and lead to anaphylactic shock; (2) certain unknown in-
gredients and adjuvants such as solubilizers and stabilizers may
increase the likelihood of allergy; (3) allergens may be produced by
oxidation, polymerization, and hydrolysis of ingredients during the
process of high-temperature sterilization or storage; and (4) the
intravenous administration of the medicine may induce a large
number of antibodies in the human body. Because of the binding
tendency of the antigen and antibody, Acanthopanax administered
as an injection could cause a higher incidence of anaphylactic
shock, compared to other administrative routs.
We suggest that Acanthopanax should be used in the oral dosage
form as much as possible, especially in patients with an allergic
constitution. After being damaged by digestive enzymes and the
breaking down of large molecules into small molecules, antigens
usually lost part or all of their antigenicity. In this paper, a 41-year-
old female patient was included who used an Acanthopanax in-
jection to cure Meniere's disease and died because of Acanthopanax
anaphylactic shock. If she had used Acanthopanax in the oral dosage
form, the result would have been entirely different. We also pro-
pose avoiding using a solvent that contains electrolytes because
salting reactions may occur and result in anaphylaxis.1
Among the reported 57 patients, most (69.56%) patients used
Acanthopanax injections that were produced by four manufac-
turers, in particular Heilongjiang Wandashan Pharmaceutical Fac-
tory. Because there were eight different manufacturers producing
Acanthopanax injections, we speculated that the manufacturers of
the Acanthopanax injections were different in their technical level.
We recommend that manufacturers should closely track adverse
reactions with the product use, improve their technical level, and
strengthen quality control. Therefore, the risk of allergic reaction in
clinical drug use could be reduced.
In 2008, Acanthopanax injections of Heilongjiang Wandashan
Pharmaceutical Factory reportedly had important safety issues.
There were > 100 adverse events, which included one death, that
occurred after the administration of their products. The Ministry of
Health (Taipei, Taiwan) ordered a halt to the use of all injections
produced by the Wandashan Pharmaceutical Factory. The ﬁndings
of this paper conﬁrm the event.
After the safety incidences by Wandashan Pharmaceutical Fac-
tory, the use of Acanthopanax injections decreased rapidly
throughout the country. Compared to the number of Acanthopanax
anaphylactic shock cases reported in the previous 10 years
(1998e2007), the number of cases of anaphylactic shock recently
decreased signiﬁcantly in a 6eyear period (2008e2013). This is
associated with the decreased use of Acanthopanax injections.
4.3. Anaphylaxis shock occurrence
According to statistical evaluations, 52 (94.54%) patients expe-
rienced anaphylactic shock in < 30 minutes after the drug's
Q. Zhan / Journal of Traditional and Complementary Medicine 5 (2015) 253e257 257administration. In all patients, the anaphylactic shock occurred
during the infusion process. For this reason, a medical staff should
closely monitor drug reactions during the infusion process, espe-
cially in the ﬁrst 30 minutes. However, because delayed-type hy-
persensitivity has been reported for other TCM injections,8 a
medical staff should not ignore a patient's reaction after a trans-
fusion. Prior to treatment, the medical staff must inform the patient
of the possibility of adverse reactions to Acanthopanax. Once an
adverse reaction occurs, the patient should get timely medical
treatment.
In this survey, anaphylactic shock occurred in two patients the
second time they used the medication, and in one patient the third
time the patient used the medication. To avoid the occurrence of
severe anaphylactic shock, Acanthopanax should not be reused once
a general allergic reaction has occurred.
4.4. Other suggestions
We suggest that the China Food and Drug Administration (SFDA)
should organize relevant experts to re-evaluate the clinical safety of
Acanthopanax injections, improve its quality standards, and be
strict with the controlling the impurity content.
5. Conclusion
Acanthopanax (刺五加 cì wǔ jia) injections can cause anaphy-
lactic shock. For severe cases, it can result in death. This should
arouse clinical medical staff and patients to attach great impor-
tance. Clinicians should adhere to the principle of rational drug use,strictly follow the indications of medication, strictly select the
treatment group, and strengthen drug monitoring during use.Conﬂicts of interest
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